NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

Active Not RecruitingPhase 2

Sponsor: Novartis Pharmaceuticals

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: VHB937, Placebo

Countries: United States, Australia, Belgium, Canada, China, Denmark, France, Germany

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* are 18 years of age or older
* male or female, if of childbearing potential, strict contraception required
* have ALS confirmed by the trial doctors using different tests.
* have mild symptoms of ALS as measured by the ALSFRS-R questionnaire (total score \>=30).
* have had symptoms of ALS (weakness) within 24 months of taking part in this trial.
* have not received treatment for ALS or are currently on a stable dose of an approved treatment for ALS.
* have the ability to slowly exhale a volume of air at least 60% of what is expected for the participant's sex, height and age.

Exclusion Criteria:

* Use of other investigational drugs within 5 half-lives of screening, or within 30 days (e.g., small molecules) / or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 24 weeks after stopping study medication.
* History or current diagnosis of cardiac conditions or ECG abnormalities indicating significant risk of safety for participants in the study.
* Clinical evidence of liver or renal disease/injury.
* Laboratory evidence of hematological abnormalities
* Presence of unstable psychiatric disease, cognitive impairment, neurological disease other than ALS, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the investigator's opinion.
* Participants that reported 'yes' on any suicidal ideation section except for the "Non-Suicidal Self-Injurious Behavior" in the past 2 years as per C-SSRS.
* Presence of cancer, HIV, Hep B, Hep C, tuberculosis, uncontrolled diabetes
* History of active severe respiratory disease, including Chronic Obstructive Pulmonary Disease, interstitial lung disease or pulmonary fibrosis.
* Taking any prohibited medications

Locations (74)

La Jolla, California, United States
Loma Linda, California, United States
Los Angeles, California, United States
San Francisco, California, United States
Miami, Florida, United States
Orlando, Florida, United States
Atlanta, Georgia, United States
Kansas City, Kansas, United States
Boston, Massachusetts, United States
Omaha, Nebraska, United States
New York, New York, United States
Rochester, New York, United States
Charlotte, North Carolina, United States
Durham, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Philadelphia, Pennsylvania, United States
Knoxville, Tennessee, United States
Austin, Texas, United States
Houston, Texas, United States
Seattle, Washington, United States
North Ryde, New South Wales, Australia
Herston, Queensland, Australia
Caulfield South, Victoria, Australia
Southport, Australia
Leuven, Vlaams Brabant, Belgium
Liège, Belgium
Calgary, Alberta, Canada
Montreal, Quebec, Canada
Beijing, China
+ 44 more on CT.gov